Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01161511 | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | PHASE1 | COMPLETED | 27 | — | — | Sep 1, 2010 | Jan 1, 2013 | Apr 21, 2014 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | XmAb5574 |
| Name | Type | Description |
|---|---|---|
| XmAb5574 | BIOLOGICAL | Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22) |
Inclusion Criteria: * relapsed or refractory CLL/SLL * at least 18 years of age * able to receive outpatient treatment and follow-up at the treating institution * completed all CLL therapies \> 4 weeks prior to first study dose Exclusion Criteria: * previously treated with an anti-CD19 antibody t...